May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
12 Month Visual Outcome Data for Patients Treated With Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. Khandhadia
    Southampton General Hospital, Southampton, United Kingdom
    Eye Unit,
  • K. Madhusudhana
    Southampton General Hospital, Southampton, United Kingdom
    Eye Unit,
  • G. Yadegafar
    Southampton General Hospital, Southampton, United Kingdom
    Public Health Sciences & Medical Statistics Division,
  • A. Lotery
    Southampton General Hospital, Southampton, United Kingdom
    Eye Unit,
  • A. Luff
    Southampton General Hospital, Southampton, United Kingdom
    Eye Unit,
  • R. Newsom
    Southampton General Hospital, Southampton, United Kingdom
    Eye Unit,
  • Footnotes
    Commercial Relationships  S. Khandhadia, None; K. Madhusudhana, None; G. Yadegafar, None; A. Lotery, None; A. Luff, None; R. Newsom, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 311. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Khandhadia, K. Madhusudhana, G. Yadegafar, A. Lotery, A. Luff, R. Newsom; 12 Month Visual Outcome Data for Patients Treated With Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):311. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the 9 and 12 month visual outcome for patients treated with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD).

 
Methods:
 

A 17 month retrospective service evaluation was carried out on 87 patients (91 eyes) treated with intravitreal bevacizumab 1.25 mg for subfoveal choroidal neovascularisation (CNV) secondary to AMD. Best-corrected visual acuity (Snellen), clinical examination, fundus fluorescein angiography and optical coherence tomography (OCT) were performed at baseline and follow-up visits.

 
Results:
 

231 injections were given (mean 2.5 injections per eye) over a mean of 9.6 months. At baseline, the mean visual acuity (calculated ETDRS) was 48.7. This improved by a mean of 4.9 letters (n=75, p=0.005), 4.7 letters (n=83, p=0.004), 5.0 letters (n=55, p=0.013), and 3.1 letters (n=35, p=0.207) at 3, 6, 9 and 12 months respectively. At last follow-up, 87.9% of eyes had stable vision (loss of <15 letters), and 28.6% gained ≥ 15 letters. There was a significant reduction (92.8 µm) of central macular thickness on OCT at the last visit compared to baseline (n=36, p<0.001). Two patients developed endophthalmitis. No systemic adverse effects were noted.

 
Conclusions:
 

The beneficial effects of intravitreal bevacizumab appear sustained at 9 months, and possibly so at 12 months, and are associated with few ocular adverse events  

 
Keywords: age-related macular degeneration • choroid: neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×